INFLUENZA REPORTER VIRUSES

Accelerating the discovery of vaccines and antiviral therapies using influenza A and B pseudoviruses

Influenza Pseudotyped Reporter Virus Particles

Influenza Components

Applications

Antibody neutralization
Serum screening
High-throughput assays

Advantages

BSL-2 use 
Stable HA sequence 
Quantitative readout

Influenza RVP Product Offerings

For your pandemic and seasonal influenza research, we offer a variety of Influenza A and Influenza B strains. We currently offer strains from the following subtypes and lineages:

Virus
Subtype or lineage
Influenza A
H1N1
Influenza A
H3N2
Influenza A
H5N1
 Influenza B
Yamagata
 Influenza B
Victoria
Related product: TiterSafe is a ready-to-use reagent that can substitute for live influenza virus in your existing hemagglutination inhibition (HAI) assay. It’s a time-saving, safer reagent for vaccine developers. To learn more and order a sample, visit TiterSafe for easy hemagglutination inhibition assays.
Need something you don’t see? We update our catalog regularly, and we can create custom RVPs to meet your needs.
SEE OUR FULL CATALOG

Integral Molecular’s Influenza Reporter Virus Particles (RVPs) are replication-incompetent pseudotyped virus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation. The RVPs display hemagglutinin (HA) and neuraminidase (NA) proteins on a heterologous virus core and carry a modified genome that expresses a convenient optical reporter gene (GFP or luciferase).

Conventional hemagglutination and microneutralization assays require handling of live and sometimes highly pathogenic BSL-3 viruses that are subject to drift upon propagation. In contrast, Influenza RVPs are a phenotypically stable, safe, and ready-to-use reagent.

RVP Readouts: agglutination and infection

Agglutination and Neut, Influenza

A) Influenza RVPs containing HA and NA proteins agglutinated red blood cells upon incubation for 1 hour. B) Infection of HEK-293T cells with Influenza RVPs was inhibited by a neutralizing monoclonal antibody (Sino #68031-H011). A non-neutralizing control antibody did not inhibit infection.

LEARN MORE ABOUT RVPS

Influenza Expertise

When you use Influenza Reporter Virus Particles, you gain access to our 20+ years of virology experience.

Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials. We also support basic virology research through collaborations and through our own peer-reviewed publications.

To see more of our publications, visit the Resources page

Ready To Get Started?

Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.

Or call (215) 966-6061